免疫抑制对非感染性葡萄膜炎的治疗作用及对细胞因子的影响

doi:10.6040/j.issn.1673-3770.0.2015.259

摘要/Abstract

摘要： 目的探讨免疫抑制对非感染性葡萄膜炎治疗作用,分析其对细胞因子的影响作用.方法将2012年7月至2014年10月诊治的57例非感染性葡萄膜炎患者,根据免疫抑制剂的药物成分不同分为激素(研究组)和激素替代制剂组(对照组),对不同免疫抑制剂对非感染性葡萄膜炎的治疗效果进行分析.结果 ① 研究组的免疫球蛋白IgA、lgG和补体C3、C4显著高于对照组;② 糖皮质激素、抗代谢药物、烷化剂、T细胞抑制剂、生物制剂的治疗总有效率较高;对细胞因子影响最大的是糖皮质激素,其次是抗代谢药物、烷化剂、T细胞抑制剂、生物制剂等.结论非感染性葡萄膜炎采用免疫抑制剂的效果显著,可以有效提高疾病治愈率,其中糖皮质激素的效果最佳,是众多药物中治疗非感染性葡萄膜炎的首选、高效药物.

关键词: 免疫抑制, 非感染性葡萄膜炎, 细胞因子, 糖皮质激素

Abstract: Objective To explore the effect of immunosuppressive treatment on noninfectious uveitis and to analyse its influence on cytokines. Methods A total of 57 patients with non-infectious uveitis treated in July 2012 to October 2012 were enrolled in this study. Based on different immunosuppressant drug ingredients, they were divided into the experimental group(hormones) and the control group(hormone preparations). Results ① The immunoglobulin Ig-A, G and C3, 4 were significantly higher in the experimental group than in the control group; ③ The greatest impact on cytokines is glucocorticoid, followed by anti-metabolites drugs, alkylating agent, T cell inhibitors, and biological preparations. Conclusion The effect of non-infectious uveitis with immune inhibitors, can effectively improve disease cure rate, of which the effect of glucocorticoid best, therefore, glucocorticoid is a wide range of drugs in the treatment of infective uveitis.

Key words: Immunosuppressive, Glucocorticoid hormone, Cytokines, Noninfectious uveitis

中图分类号:

R773

王增智. 免疫抑制对非感染性葡萄膜炎的治疗作用及对细胞因子的影响[J]. 山东大学耳鼻喉眼学报, 2015, 29(6): 64-67.

WANG Zengzhi. Immunosuppressive treatment for non-infectious uveitis and its effect on cytokines[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(6): 64-67.

参考文献

[1] 于晋懿,卢弘.非感染性葡萄膜炎的免疫抑制治疗[J].眼科新进展,2014,34(7):695-700. YU Jinyi, LU Hong. Immunosuppressive therapy for noninfectious uveitis[J]. Rec Adva Ophthalmol, 2014, 34(7):695-700.
[2] 卢弘,余烁.非感染性葡萄膜炎的临床治疗指南及当前实际治疗模式的研究启示[J].中华眼科医学杂志:电子版,2013,3(5):263-267. LU Hong, YU Shuo. The practice guideline of non-infectious uveitis and the revelation of current studies on actual treatment modalities[J]. Chin J Ophthalmol Med Electr Ed, 2013, 3(5):263-267.
[3] Markomichelakis N, Dilieha E, Masselos S, et al. A single infliximab infusion is corticosteroids for acute panuveitis attacks in Behcet's disease: a comparative 4-week study[J]. Rheumatol(Oxford), 2011, 50(3):593-597.
[4] 孙晓茹,毕宏生,郭俊国.青蒿素及其衍生物免疫抑制作用在防治葡萄膜炎中的前景[J].国际眼科杂志,2012,12(6):1078-1080. SUN Xiaoru, BI Hongsheng, GUO Junguo. Prospect of immunosuppression of Artemisinin and its derivatives in uveitis control[J]. Inter Eye Sci, 2012, 12(6):1078-1080.
[5] Matsuda J, Kaburaki T, Kobayashi S, et al. Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis [J]. Jpn J Ophthalmol, 2013, 57(1):104-107.
[6] 刘晓菊.自身免疫性葡萄膜炎的免疫疗法研究进展[J].北方药学,2011,8(4):29-30. LIU Xiaoju. Research progress of autoimmune uveitis immunotherapy[J]. Beifang Yaoxue, 2011, 8(4):29-30.
[7] Artornsombudh P, Gevorgyan O, Payal A, et al. Infliximab treatment of patients with birdshot retinochoroidopathy[J]. Ophthalmology, 2013, 120(3):588-592.
[8] 刘雪霞.葡萄膜炎的病因及治疗进展[J].中华眼科医学杂志:电子版,2014,12(1):39-42. LIU Xuexia. Progress in the etiology and treatment of uveitis[J]. Chin J Ophthalmol Med Electr Ed, 2014, 12(1):39-42.
[9] 任亚琳,王增智,王艳丽,等.环孢霉素A对葡萄膜炎中IL-17⁺细胞的作用机制[J].国际眼科杂志,2012,12(6):1054-1055. REN Yalin, WANG Zengzhi, WANG Yanli, et al. Study on the mechanisms of CsA on the IL-17⁺cells in the uveitis patients[J]. Inter Eye Sci, 2012, 12(6):1054-1055.
[10] Van Dartel S A, Fransen J, Kierit W, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis monitoring(KREAM) registry[J]. Ann Rheum Dis, 2013, 72(6):895-900.
[11] 温鑫.CD4⁺T细胞与非感染性葡萄膜炎[J].眼科研究,2010,28(6):560-564. WEN Xin. CD4⁺T cell and non-infectious uveitis[J]. Chin Ophthal Res, 2010, 28(6):560-564.
[12] 张莲,毕宏生,郭俊国.抗TNF生物制剂在葡萄膜炎临床治疗中的应用进展[J].眼科新进展,2014,34(12):1187-1189, 1196. ZHANG Lian, BI Hongsheng, GUO Junguo. Application progress of anti-TNF biologic agents for uveitis[J]. Rec Adv Ophthalmol, 2014, 34(12):1187-1189, 1196.

相关文章 15

[1]	黄远,巴罗,李波,余文兴,杨芳丽,杜进涛. 慢性鼻窦炎鼻息肉中转录因子NKX2-1调控嗜酸性炎症反应的作用[J]. 山东大学耳鼻喉眼学报, 2018, 32(4): 17-23.
[2]	黄凯丰. 糖皮质激素短疗程雾化吸入对嗜酸粒细胞性鼻窦炎伴鼻息肉患者鼻部症状及肾上腺皮质功能的影响[J]. 山东大学耳鼻喉眼学报, 2018, 32(4): 28-31.
[3]	李华斌, 赖玉婷. 慢性鼻-鼻窦炎的发病机制及诊疗进展[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 4-9.
[4]	谢洪彬,杨美娜,陈青山,刘旭阳,樊宁. IgG4相关性眼病伴继发性青光眼病例分析[J]. 山东大学耳鼻喉眼学报, 2018, 32(2): 99-102.
[5]	高进良,年婉清,李烁. 鼻内镜手术联合鼻用糖皮质激素治疗腺样体肥大性[J]. 山东大学耳鼻喉眼学报, 2018, 32(2): 38-42.
[6]	史丽,赵莉,张红萍. 变应性鼻炎的长期抗炎治疗[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 9-12.
[7]	童尧,郑岩,周雅丽,王艺晓,赵培泉,汪朝阳. 各型青光眼患者眼内TNF-α及IP-10水平及其相关性分析[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 103-106.
[8]	刘叶,孙殿水,殷进军,夏明,徐英,孙建华. 鼻咽癌调强放疗后前庭功能损伤的机制研究[J]. 山东大学耳鼻喉眼学报, 2016, 30(6): 14-17.
[9]	包扬,王春玲,张丽,金敏,周长青,潘新良. 帕瑞昔布钠联合曲马多镇痛对悬雍垂腭咽成形术患者的影响[J]. 山东大学耳鼻喉眼学报, 2016, 30(5): 49-53.
[10]	张革化,李文婷. 变应性鼻炎的药物治疗策略[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 10-14.
[11]	姜海华. S-100蛋白和HLA-DR在鼻息肉组织中的表达[J]. 山东大学耳鼻喉眼学报, 2015, 29(3): 43-45.
[12]	卢娜. 三种不同给药途径治疗突发性感音神经性耳聋的效果对比[J]. 山东大学耳鼻喉眼学报, 2015, 29(2): 24-27.
[13]	张清照1，嶋田貴志2，程雷1. 肠球菌属益生菌提取物LFK对变应性鼻炎小鼠血清IL-12的影响[J]. 山东大学耳鼻喉眼学报, 2014, 28(3): 7-9.
[14]	张丽净1,2，宋西成1，贾传亮1,3，王晓勇1,3，张华1，王强1. 血清中炎症介质和细胞因子与儿童腺样体肥大相关性研究[J]. 山东大学耳鼻喉眼学报, 2014, 28(2): 58-61.
[15]	王卫之1，张丙峰2，刘少华1，王欣2. 系统性糖皮质激素+沙利度胺治疗口咽部重型阿弗他溃疡[J]. 山东大学耳鼻喉眼学报, 2013, 27(6): 72-73.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed